ArticleOpen forum infectious diseases2019
Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among
Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06305455 (Change in the Resistance Profile of Escherichia Coli in Infections of Community Origin), which is not on this map. Cited by 94 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Change in the Resistance Profile of Escherichia Coli in Infections of Community Origin: The Importance of Antimicrobial Stewardship
Who cites it
94 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Trial
- Carbapenemase-producing Enterobacterales infections: a real-world cohort study from a secondary hospital in Shanghai, China.BMC infectious diseases · 2026Article
- Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in β-Lactamase Inhibitor Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Epidemiological Insights into Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Activity of aztreonam-avibactam, cefiderocol, and cefepime-taniborbactam against a global collection of genetically characterized metallo-β-lactamase-producing Enterobacterales.Antimicrobial agents and chemotherapy · 2026Article
- Innovative Antibiotics: The Experience of Cefiderocol in Carbapenem-Resistant Gram-Negative Infections.Infection and drug resistance · 2026Review
- Clinical impact of broad- versus narrow-spectrum empiric therapy in acute cholangitis: A Japanese claims database study.PloS one · 2026Article
- Global Epidemiology and Antimicrobial Resistance of Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Gram-Negative Clinical Isolates: A Review.Microorganisms · 2025Review
- Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review.JAC-antimicrobial resistance · 2025Review
- Carbapenem-resistant Enterobacterales bloodstream infections related to death in two Brazilian tertiary hospitals.BMC infectious diseases · 2025Article
- Antimicrobial resistance and vaccines in Enterobacteriaceae including extraintestinal pathogenic Escherichia coli and Klebsiella pneumoniae.npj antimicrobials and resistance · 2025Review
- Whole Genome Sequencing Analysis ofOpen forum infectious diseases · 2025Article
- Patient characteristics and antimicrobial susceptibility profiles of Escherichia coli and Klebsiella pneumoniae infections in international travellers: a GeoSentinel analysis.Journal of travel medicine · 2025Article
- Antimicrobial Resistance in Gram-Negative Bacterial Pneumonia After the COVID-19 Pandemic in Northern Iran.Advanced biomedical research · 2025Article
- Risk factors, and outcomes of patients with carbapenem-resistantFrontiers in cellular and infection microbiology · 2025Article
- Post-liver transplantation bacterial infection: current status, prevention and treatment.Frontiers in cellular and infection microbiology · 2025Review
- Article
- Clinical and Microbiological Characteristics of Carbapenem-ResistantInfection and drug resistance · 2025Article
- National Multicenter Study on the Prevalence of Carbapenemase-Producing Enterobacteriaceae in the Post-COVID-19 Era in Argentina: The RECAPT-AR Study.Antibiotics (Basel, Switzerland) · 2024Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA total of 178 825
methodsTrends in percentages over time were analyzed by the χ
results
conclusionsA change in the epidemiology of carbapenemases and important increases in ESBL, CRE, MDR, and other resistant phenotypes among virtually all geographic regions and infection sources were noted in the 20 years of surveillance, highlighting the impact of antimicrobial resistance and the importance of its continuous monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.